Nicolas GAZEAU

Hématologue au CHRU de Lille.

[Nicolas GAZEAU @NGazeau14]

Very happy to share our work on therapy-related myeloid neoplasms (t-MN) post-CD19 CAR T-cell therapy, published in @LeukemiaJnl and involving 4 French centers (@CHU_Lille, Lyon, Caen, St-Étienne).
🔗 https://t.co/lVrcI9P1B7

#CAR_T #Lymphoma #tMN #Hematology

[nizar jacques bahlis @NBahlis]

My summary of CARTITUDE4, MajesTEC3, MajesTEC9 and MoumenTAL3. In anti-CD38 refractory patients and EMDs -->TCE anti-BCMA or anti-GPRC5D are >> to Cilta-Cel

[Ajay Major, MD, MBA @majorajay]

Does HD-MTX ppx reduce CNS relapse even in ultra-high-risk LBCL? #lymsm
- >1900 pts, all CNS-IPI 5-6; testicular, renal/adrenal, breast; ≥3 EN sites
- 3-yr CNS relapse: 9.3% (no HD-MTX) v 8.1% (HD-MTX), adjusted HR 1.13 [0.82, 1.57]
- no diff in isolated CNS relapse: 5.9% v 5.7%
- no diff in relapse rates for any high-risk subtypes
- DHL/THL not included
End of HD-MTX ppx, although DHL/THL is still a question. cc @tobyeyre82 @mattwilson2287
https://t.co/80zAeJmlXo

[CAR T day @CARTday_]

Save the Date! Get ready for CAR T day, the 10th International Symposium on CAR T cells! 🎉

📅 When: September 10-11, 2026
📍 Where: Lille, France, at the Faculty of medecine

🔬Why you should attend

For our 10th edition, we are preparing a cutting-edge science and collaborative exchange on:
- The latest advances in CAR T cell therapies
- Innovations in treatment for B-cell malignancies
- New frontiers in solid tumors and autoimmune diseases
- Future challenges and solutions in cancer care

👥 A must-attend event for clinicians, researchers, pharmacists, healthcare professionals & anyone shaping the future of cancer treatment and immunotherapy.

🌍 International experts will share insights on:
- CAR T cell production & development
- Emerging therapeutic strategies
And much more!

Registrations will open very soon... 📢 Don't miss any information & subscribe to our newsletter 👉 https://t.co/FOjEGgB437

To know more 👉 https://t.co/pxCeAKFwZp

[Jordan Gauthier @drjgauthier]

Dr. @emilyliangmd expertly presenting at #ASH25 the largest study to date diving into the use of anakinra for refractory/severe ICANS (n=101).
We benchmark key clinical outcomes, and identify potential predictive biomarkers of anakinra efficacy.
Prospective comparative studies critically needed!
#CARTx #anakinra #CARTOX @OHSUNews

[Lymphoma Hub @lymphomahub]

CONGRESS | #ASH25 | PRESENTATION
Alice Di Rocco shares data from the first analysis of phase 2 FIL_RI-CHOP study evaluating ibrutinib + R-CHOP in untreated ABC-DLBCL with IPI ≥ 2 (N = 75).
ORR was 90% at cycle 4 and 85% at EOT. 2-year PFS was 77.7%. Grade 3/4 neutropenia and febrile neutropenia was 33% and 4%, respectively.
Follow our live feed for more updates: https://t.co/QvRGEzgS3d
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#lymphoma #lymsm #MedicalCongress @unirome1

[Rémy Duléry @RemyDulery]

Outstanding presentation by @Gabriel_Brisou 👏

After rigorous sIPTW adjustment, axi-cel and liso-cel show comparable PFS/OS in 2L R/R LBCL, with a clearly more favorable safety profile for liso-cel.

Great work from @lysalymphoma and DESCAR-T teams!
#ASH25

[Ajay Major, MD, MBA @majorajay]

Fun #ASH25 abstract: CD19 CAR in CD19-negative LBCL
- 211 pts: 18% CD19neg before CAR (all 3L+)
- no diff CRS, much less ICANS if CD19neg
- no diff CR/ORR/PFS/OS between CD19+ and CD19-
Tumor heterogeneity?! Great question to ask. #lymsm #tcellrx

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Novel antibodies for identification, selection, and manipulation of T cells expressing Whitlow linker-containing CARs https://t.co/k6DFXlT8dg
@ekimblepl @drjgauthier @fredhutch

[Jordan Gauthier @drjgauthier]

Our ICAHTologist Dr. @emilyliangmd giving a great overview of her work at the Seattle Cellular Therapy Summit @binaytara aimed at characterizing hematotoxicity after CAR T-cell therapy.
More to come on that note soon! 😉
@fredhutch

[Jordan Gauthier @drjgauthier]

I was lucky to lead this @CIBMTR analysis just published in @AjHematology 👇
https://t.co/5JtisXr3Tz
🔑 findings:
💡 CD19 CAR T-cell therapy leads to high rates of durable responses in patients with primary mediastinal large B-cell lymphoma (PMBCL): ORR 79% CRR 68% 2-year PFS 58.6%. Outcomes may be superior compared to other LBCL subtypes.
💡We observed significantly lower relapse rates in patients exposed to immune checkpoint inhibitors prior to CAR T-cell therapy with ~50% absolute reduction in relapse incidence in ICI-exposed (2-year cumulative incidence of relapse: 21.7%) compared to ICI-naive patients (41.6%).
💡Prior ICI exposure was not associated with higher rates or severity of early toxicities such as cytokine release syndrome and neurotoxicity.

❓More data needed to better characterize how ICIs impact CAR T-cell function and TME in patients with PMBCL

🙏All collaborators and co-authors @mshadman @fredhutch @NatalieGroverMD @BradHaverkos @DrMarcosdelima @AMalone2012 @LauriePearsonMD @AnnaSureda5 @Kwudhikarn @samyamshon + others not on X.
Special thanks to @MediHumdani @MedicalCollege and Senior Author Dr. Alex Herrera @cityofhope for their guidance and for putting up with me! 😅

👉Please share with your network if you learnt something with this post 🙏
#HemOnc #MedEd #lymphomasm #CARTcelltherapy

[Graham Collins @graham74GC]

Kamdar et al; 3y FU of TRANSFORM study - Liso-cel vs standard 2nd line in 1st relapse large B-cell NHL.

Impressive PFS & EFS benefit
Trend to OS but not stat significant. 66% crossed over to liso-cel from control arm.

No new tox signal.

https://t.co/LSZ4irLYH2

[Ajay Major, MD, MBA @majorajay]

2nd myeloid cancers post CD19 CAR @NGazeau14
- 539 pts, all B-NHL
- 2-yr cumulative risk t-MN: 4.5% (10% at 4 yrs!)
- ⬆️ MCV & high-grade ICANS risk factors for t-MN
- 86% of t-MN had pre-CAR mutations
Important retrospective study for #tcellrx. #lymsm
https://t.co/hdKyrcHPPA

[Nicolas GAZEAU @NGazeau14]

@majorajay Thank you for sharing, really appreciated.🙏

[Nicolas GAZEAU @NGazeau14]

Many thanks to Pierre Sesques and David Beauvais for making this collaboration possible, as well as to all our fantastic contributors! @RemiTilmont @NicolasGower @AghaYakoub10634 @benjamin_podvin @NicolasDuployez

[Nicolas GAZEAU @NGazeau14]

Very happy to share our work on therapy-related myeloid neoplasms (t-MN) post-CD19 CAR T-cell therapy, published in @LeukemiaJnl and involving 4 French centers (@CHU_Lille, Lyon, Caen, St-Étienne).
🔗 https://t.co/lVrcI9P1B7

#CAR_T #Lymphoma #tMN #Hematology

[Nicolas GAZEAU @NGazeau14]

Key findings:
- Incidence of 4.5% at 2 years
- t-AML (38%) & t-MDS (62%)
- Median OS of 4.5 months
- Risk Factors after matching : preLD MCV & higher ICANS grade remained significant
- CD28 domain trended towards higher t-MN risk
- Pre-existing Mutations: 85.7%, TP53 (50%)

[Nicolas GAZEAU @NGazeau14]

Congrats Boss! 🫡

@i_yakoub_agha @TheEBMT
#EBMT25 #EBMT2025

[IACH @TheIACH]

🎊@TheIACH Congratulates Prof. Ibrahim Yakoub- Agha

Ibrahim Yakoub-Agha is the new
EBMT President-Elect
⬇️⬇️
https://t.co/77U0fPiL4q

@i_yakoub_agha @Mohty_EBMT @TheEBMT
#EBMT25 #EBMT2025

[Razan Mohty @Razan_Mohty]

Happy to share our recent manuscript on outcomes of anti-CD19 #CART for #lymphoma in octogenarians (80 years of age or older).

👉🏻CR rate 71.4%
👉🏻1-year OS 61.2%
👉🏻1-year PFS 47.6%
👉🏻1-year NRM 11.6%

🙏🏻 to all collaborators

Link 🔗 https://t.co/F4D3hIWWBC

[Nicolas GAZEAU @NGazeau14]

@drjgauthier @5_utr @RemiTilmont 🫡

[ASTCT @ASTCT]

Congratulations to ASTCT New Investigator Award recipient Erik Kimble, MD, of @fredhutch. #Tandem25